

AMENDMENTS TO THE CLAIMS:


This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-8. (Canceled)


Claim 9. (Previously Presented) A method for treating a disease and/or condition associated with the excessive release of glutamate selected from the group consisting of epileptic seizures, acute neurodegenerative diseases, chronic neurodegenerative diseases, drug-induced neurotoxicity, pain, hormonal balance disorders, thermoregulation disorders, respiration disorders, learning disorders, pattern recognition disorders, memory disorders, and disorders subsequent to hypoxia or hypoglycaemia in a patient comprising administration to said patient of a composition containing a therapeutically effective amount of at least one beta-naphthoquinone derivative and a pharmaceutically acceptable carrier, wherein said beta-naphthoquinone derivative is selected among the group consisting of:

(i) compounds having the formula (I):



wherein R represents -NH-CO-NH₂, -NH-CO-CH₃, or -OH group,

(ii) glucuronide derivatives thereof having the formula (II):



wherein R is as indicated in (i), and

(iii) addition salts thereof.

Claim 10. (Previously Presented). The method of claim 9, wherein said beta-naphthoguinone derivative is selected among the group consisting of the 1,2-naphthoquinone, 2-semicarbazone and the 1-(1-hydroxy,2-naphthyl)semicarbazide-1- β -O-glucopyranosiduronic acid.


Claim 11. (Canceled).

Claim 12. (Previously Presented) The method of claim 9, wherein said disease and/or condition is an acute or chronic neurodegenerative disease selected from the group consisting of Alzheimer's disease, Huntington's disease, Parkinson's disease, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), retinopathy, stroke, and traumatic brain injury.

Claim 13 (New) A method for treating Alzheimer's disease in a patient comprising administration to said patient of a composition containing a therapeutically


effective amount of at least one beta-naphthoquinone derivative and a pharmaceutically acceptable carrier, wherein said beta-naphthoquinone derivative is selected among the group consisting of:

(i) compounds having the formula (I):



wherein R represents -NH-CO-NH₂, -NH-CO-CH₃, or -OH group,

(ii) glucuronide derivatives thereof having the formula (II):



wherein R is as indicated in (i), and


(iii) addition salts thereof.

Claim 14. (New). The method of claim 13, wherein said beta-naphthoquinone derivative is selected among the group consisting of the 1,2-naphthoquinone, 2-

semicarbazone and the 1-(1-hydroxy,2-naphthyl)semicarbazide-1- β -O-gluco-pyranosiduronic acid.


Claim 15 (New) A method for treating Parkinson's disease in a patient comprising administration to said patient of a composition containing a therapeutically effective amount of at least one beta-naphthoquinone derivative and a pharmaceutically acceptable carrier, wherein said beta-naphthoquinone derivative is selected among the group consisting of:

(i) compounds having the formula (I):



wherein R represents -NH-CO-NH₂, -NH-CO-CH₃, or -OH group,

(ii) glucuronide derivatives thereof having the formula (II):



wherein R is as indicated in (i), and

(iii) addition salts thereof.

Claim 16. (New). The method of claim 15, wherein said beta-naphthoguinone derivative is selected among the group consisting of the 1,2-naphthoquinone, 2-semicarbazone and the 1-(1-hydroxy,2-naphthyl)semicarbazide-1- β -O-gluco-pyranosiduronic acid.